PYY3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans
BCT Field, AM Wren, V Peters, KCR Baynes… - Diabetes, 2010 - Am Diabetes Assoc
BCT Field, AM Wren, V Peters, KCR Baynes, NM Martin, M Patterson, S Alsaraf, V Amber…
Diabetes, 2010•Am Diabetes AssocOBJECTIVE Peptide YY3–36 (PYY3–36), a Y2 receptor agonist, and oxyntomodulin, a
glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after
each meal. Separately each hormone acts as an endogenous satiety signal and reduces
appetite in humans when infused intravenously. The aim of the current study was to
investigate whether the anorectic effects of PYY3–36 and oxyntomodulin can be additive.
RESEARCH DESIGN AND METHODS Twelve overweight or obese human volunteers …
glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after
each meal. Separately each hormone acts as an endogenous satiety signal and reduces
appetite in humans when infused intravenously. The aim of the current study was to
investigate whether the anorectic effects of PYY3–36 and oxyntomodulin can be additive.
RESEARCH DESIGN AND METHODS Twelve overweight or obese human volunteers …
OBJECTIVE
Peptide YY3–36 (PYY3–36), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal. Separately each hormone acts as an endogenous satiety signal and reduces appetite in humans when infused intravenously. The aim of the current study was to investigate whether the anorectic effects of PYY3–36 and oxyntomodulin can be additive.
RESEARCH DESIGN AND METHODS
Twelve overweight or obese human volunteers underwent a randomized, double-blinded, placebo-controlled study. An ad libitum test meal was used to measure energy intake during intravenous infusions of either PYY3–36 or oxyntomodulin or combined PYY3–36/oxyntomodulin.
RESULTS
Energy intake during coadministration of PYY3–36 and oxyntomodulin was reduced by 42.7% in comparison with the saline control and was significantly lower than that during infusions of either hormone alone.
CONCLUSIONS
The anorectic effects of PYY3–36 and oxyntomodulin can be additive in overweight and obese humans. Coadministration of Y2 receptor agonists and GLP-1 receptor agonists may be a useful treatment strategy for obesity.
Am Diabetes Assoc